Patent ID: 7759306

Claim:
A method for treating severe acute blood loss anemia in a subject, comprising administering to the subject in need thereof a cross-linked hemoglobin blood substitute in an amount effective to elevate blood volume and counteract hypoxia associated with the severe acute blood loss anemia in the subject, wherein the cross-linked hemoglobin blood substitute (i) when tested in a cell culture under normoxic conditions, induces expression of erythropoietin; or (ii) induces erythropoiesis under normoxic conditions as measured by a decrease in the doubling time of the subject's hematocrit or hemoglobin; or (iii) induces erythropoiesis under normoxic conditions as measured by an increase in the subject's circulating erythropoietin level, wherein the cross-linked hemoglobin blood substitute, when tested in a cell culture, stabilizes HIF-1 alpha expression.